C

CTSO

CTSO

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
53%Neutral
Buy/Sell Ratio100% buys
BearishBullish
CTSO Live QuoteReal-time
$4.16
$1.85(-30.78%)1M
Day Range$4.16 – $5.14
Open$5.14
Previous Close$5.13
Volume28.8K
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$13.11M
P/E Ratio (TTM)24.5
Forward P/E7.2
EPS (TTM)$-5.62
Price to Book11.4
Dividend Yield0.65%
Beta (Volatility)1.48
IndustryMEDICAL DEVICES
52-Week RangeCurrent: $4.16 (9%)
Low: $2.84High: $17.00
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$32.50-78.3% upside

Insider Buys

8

$317K

Insider Sales

0

$0

Total Volume

$317K

15 transactions

Net Activity

+$317K

Net buying

Proprietary Ratings
Calculated from Form 4 transactions
100CONFIDENCE

Sentiment Rating

Strong Accumulation

CEO Conviction Index

High Conviction Accumulation

Key Drivers

  • •Strong buying bias: purchases represent 100% of total transaction value.
  • •Cluster buying: 4 unique insiders purchased shares, showing strong alignment.
  • •CEO buying activity detected. When chief executives put their own money at risk, it is historically a strong bullish signal.
  • •CFO buying activity detected. Statistical studies show CFO purchases have high predictive power due to their direct visibility into balance sheet details.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
M
1

Multiple Insiders

P - Purchase Insiders

0 buys7 sells

$929.27B total

C
2

Chan Phillip P.

CEO

3 buys0 sells

$198K total

M
3

Mariani Peter J

CFO

3 buys0 sells

$91K total

S
4

Sobel Alan D.

Dir

1 buys0 sells

$15K total

C
5

Capponi Vincent

Pres, COO

1 buys0 sells

$13K total

Trading History
CTSO insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Sep 15, 2026

2 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell101.0K$3774.00$381.16M

Sep 14, 2026

2 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell40.4K$2073.00$83.72M

Sep 15, 2026

2 months ago

Chan Phillip P.

CEO

CEO
Buy3.8K$6.00$23K

Sep 14, 2026

2 months ago

Capponi Vincent

Pres, COO

COO
Buy2.1K$6.05$13K

Sep 15, 2026

2 months ago

Sobel Alan D.

Dir

Director
Buy2.5K$6.10$15K

Sep 4, 2026

2 months ago

Chan Phillip P.

CEO

CEO
Buy200.0K$0.35$70K

Sep 4, 2026

2 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell1.94M$200000.00$388.89B

Jun 15, 2026

5 months ago

Mariani Peter J

CFO

CFO
Buy100.0K$0.44$44K

Jun 15, 2026

5 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell638.1K$100000.00$63.81B

Jun 12, 2026

5 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell1.74M$261469.00$456.11B

Jun 12, 2026

5 months ago

Chan Phillip P.

CEO

CEO
Buy261.5K$0.40$105K

Dec 13, 2024

23 months ago

Mariani Peter J

CFO

CFO
Buy20.0K$0.96$19K

Dec 13, 2024

23 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell401.4K$20000.00$8.03B

Dec 11, 2024

23 months ago

Mariani Peter J

CFO

CFO
Buy31.4K$0.89$28K

Dec 11, 2024

23 months ago

Multiple Insiders

P - Purchase Insiders

Insider
Sell381.4K$31363.00$11.96B
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction4%
CTSO Buy Conviction100%
Industry Rank#0 of 584
Volume Contribution0.0%
Total Industry Activity$17.22B

CTSO has an insider buy conviction of 100%, compared to the Unknown sector buy average of 4%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for CTSO

Over the last 90 days, corporate insiders at CTSO (CTSO) engaged in a total of 15 transactions reported via SEC Form 4 filings. Among these, 8 were open-market purchases and 0 were sales. The total volume of insider trading reached $317K.

The net insider activity for CTSO shows a net buying bias of $317K. This activity represents a 100% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 1.74M shares valued at $456.11B on Jun 12, 2026.

Live Market News & Developments
Aggregated real-time headlines for CTSO (CTSO)
6 updates

Cytosorbents Corporation 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:CTSO) 2026-11-17

Seeking Alpha3d ago

CytoSorbents Corporation (CTSO) Raises $4.0M and Restructures Debt

TradingViewYesterday

About $700,000 in interest savings are expected over 12 months as CytoSorbents extends its loan maturity to 2028.

Stock TitanYesterday

CytoSorbents Announces Reverse Stock Split

PR Newswire79d ago

Cytosorbents Faces Nasdaq Compliance and Delisting Risk

The Globe and Mail137d ago

CTSO - Cytosorbents Corp Stock Price and Quote

Finviz177d ago

FAQs About CTSO Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for CTSO.

Based on SEC Form 4 disclosures, the Insider Confidence Score for CTSO is currently 100/100, which reflects a strong accumulation bias. This calculation accounts for a total of 8 purchases and 0 sales by company executives over the last 90 days.

The CEO Conviction Index for CTSO is rated as "High Conviction Accumulation". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.